Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06630325
Title	A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced, Recurrent Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
Recruitment	Not yet recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	OHSU Knight Cancer Institute
Indications	ovarian cancer breast cancer sarcoma prostate cancer pancreatic cancer
Therapies	Fulvestrant Olaparib + Pegylated liposomal doxorubicin Abemaciclib + Letrozole Abemaciclib Olaparib Olaparib + Temozolomide Abemaciclib + Tamoxifen Abemaciclib + Gemcitabine Gefitinib Abemaciclib + Pemetrexed Disodium Abemaciclib + Exemestane Osimertinib Carboplatin + Gefitinib + Pemetrexed Disodium Carboplatin + Olaparib + Paclitaxel
Age Groups:	adult \| senior
Covered Countries	USA